Schrödinger

90 articles with Schrödinger

• Schrödinger and Qu & Co Announce Collaboration to Advance Quantum Mechanical Computations on Quantum Computers

  9/3/2019

  Schrödinger and Qu & Co announced a business and scientific collaboration to advance the use of quantum mechanics on complex molecular systems using quantum computing hardware.

• Schrödinger Expands Drug Discovery Partnership with Morphic Therapeutic

  8/13/2019

  Extended collaboration leveraging Schrödinger’s computational platform includes new terms with increased and additional milestone payments to Schrödinger

• Schrödinger Appoints Veteran Pharma Financial Leader Gary Sender to Board of Directors

  8/5/2019

  Mr. Sender brings over 30 years of financial leadership experience, with a strong track record of success.

• Schrödinger Receives Milestone Payment from Ono as Collaborative Program Advances

  7/12/2019

  Schrödinger announced receipt of a milestone payment from Ono Pharmaceutical Co., Ltd. as part of a collaboration leveraging Schrödinger’s advanced computational platform to develop novel therapeutic candidates acting on the therapeutic target selected by Ono.

• Schrödinger Receives Milestone Payment from Sanofi Collaboration

  7/11/2019

  Milestone marks advancement of second drug discovery program under the collaboration

• Schrödinger Bolsters Translational Science Expertise with Leadership Expansion

  6/19/2019

  New hires to lead ADME/PK and Clinical Pharmacology for rapidly advancing internal pipeline programs

• 

  Schrödinger's Financing Round Increases to $110 Million With New Investor Support

  5/21/2019

  The financing is expected to be used to advance the company’s computational platform, as well as expand Schrödinger’s therapeutic pipeline.

• Schrödinger Announces Close of Latest Financing, Raising Total of $110 Million

  5/19/2019

  New funding to support platform advancements and proprietary pipeline expansion

• Schrödinger to Present at May Conferences

  5/13/2019

  Schrödinger announced that the Company will be presenting on its advanced computational platform, which integrates physics-based molecular simulation and machine learning to accelerate drug discovery, at the upcoming conferences in May

• Schrödinger Receives Clinical-Stage Milestone Payment from Sanofi Collaboration

  4/8/2019

  The companies are currently advancing programs in oncology and autoimmune disease.

• 

  BioSpace Movers and Shakers: March 29

  3/29/2019

  Biotech and pharma companies bring on new talent to strengthen leadership teams and boards.

• Schrödinger Appoints Professor Brian Shoichet to Scientific Advisory Board

  3/26/2019

  Schrödinger announced the appointment of Professor of Chemistry Brian Shoichet, Ph.D., a widely published thought leader in the field of computational drug discovery, to its scientific advisory board.

• Schrödinger Appoints Veteran Biotech Industry Leader Dr. Rosana Kapeller to Board of Directors

  1/23/2019

  Schrödinger today announced the appointment of veteran biotech leader Rosana Kapeller, M.D., Ph.D., to its board of directors.

• Schrödinger Closes $85 Million Financing to Advance Computational Platform and Expand Drug Discovery Pipeline

  1/4/2019

  Investment in R&D will extend capabilities of computational platform and support growth of partnered and proprietary programs

• Schrödinger and TB Alliance Announce Collaboration to Accelerate Tuberculosis Drug Discovery

  12/11/2018

  Partnership merges Schrödinger’s advanced modeling capabilities with TB Alliance’s expertise in tuberculosis biology to accelerate the development of next-generation treatments

• Schrödinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program

  12/3/2018

  Collaboration brings together Schrödinger’s in silico discovery capabilities with SPARC’s novel insights into CNS pathways to speed drug development

• 

  BioSpace Movers and Shakers for Nov. 19

  11/19/2018

  Companies bolstered their leadership with additions to boards of directors and c-suite offices.

• Schrödinger Names Veteran Pharma Executive Joel Lebowitz as Chief Financial Officer

  11/15/2018

  Mr. Lebowitz, a longtime senior executive at Merck, brings to the company deep experience in finance and business development.

• Schrödinger and WuXi AppTec Announce the Launch of Faxian Therapeutics to Enable Accelerated Drug Discovery

  10/30/2018

  The new venture will leverage the precision molecular design platforms developed by Schrödinger and accelerate them through partnership with the world-class lead optimization services provided by WuXi AppTec.

• Schrödinger to Participate in Citi 13th Annual Biotech Conference

  8/30/2018

  Schrödinger, Inc. announced today that the Company will participate in a panel discussion entitled "Emerging Innovators - An Introduction to Biotech Privates" at the Citi 13th Annual Biotech Conference